• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Zoliflodacin (ETX0914) effectively treats urogenital gonorrhea

byDayton McMillan
November 8, 2018
in Chronic Disease, Infectious Disease, Obstetrics, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Patients with uncomplicated urogenital gonorrhea treated with the novel antibiotic zoliflodacin, developed in part due to increasingly antibiotic resistant gonorrhea, were cured at rates similar to that seen in patients treated with ceftriaxone.

2. Patients with pharyngeal gonorrhea infection appear to be cured at a higher rate when treated with ceftriaxone compared to zoliflodacin.

Evidence Rating Level: 2 (Good)         

Study Rundown: Gonorrhea is being diagnosed in the United States at increasing rates, while at the same time many strains are becoming resistant to drugs commonly used for treatment. Zoliflodacin is a novel antibiotic which works by inhibiting DNA synthesis, different from currently used antibiotic regimens, and has been shown effective in vitro when evaluated in strains of ciprofloxacin and ceftriaxone resistant gonorrhea. Zoliflodacin also has shown activity against chlamydia and mycoplasma species. This phase 2 trial evaluated the efficacy of single dose oral zoliflodacin compared to intramuscular ceftriaxone for the treatment of uncomplicated urogenital gonorrhea. The primary outcome, microbiologically determined cure at 1 week, was similar for patients with uncomplicated urogenital gonorrhea treated with either zoliflodacin or ceftriaxone. Patients with pharyngeal gonorrhea were cured at lower rates when treated with zoliflodacin compared to ceftriaxone.

The study confirmed the feasibility of utilizing zoliflodacin for the treatment of urogenital gonorrhea. Its strengths include its randomized and multicenter design, determination of cure by microbiologic testing, and collection of patient gonorrhea isolates for further testing. Limitations include its limited number of patients included, low number of included women, and limited cases of rectal or pharyngeal gonorrhea.

Click to read the study, published today in NEJM

In-Depth [randomized controlled trial]: This phase 2, multicenter, randomized controlled trial enrolled patients between 2014 and 2015. Eligible patients were between 18 and 55 with signs or symptoms of urogenital gonorrhea, untreated gonorrhea, or sexual contact within the last 14 days with a person with gonorrhea, and abstained from sexual contact for 7 days after treatment. Patients with complicated gonorrhea were excluded. Patients were randomized to receive zoliflodacin in a 2g (n=57) or 3g (n=56) oral dose, or 500mg of intramuscular ceftriaxone (n=28). Samples were obtained from all patients prior to treatment at urethral/cervical, pharyngeal, and rectal sites and underwent nucleic acid amplification testing (NAAT). Patients were then tested at the same sample sites both approx. 7 and 31 days after treatment. The primary outcome, NAAT determined urogenital cure at 7 days, was present in 96% of both of the zoliflodacin groups and 100% of the ceftriaxone groups. Among patients with positive pharyngeal samples, 4/8, 9/11, and 4/4 patients were cured at 1 week when treated with 2g zoliflodacin, 3g zoliflodacin, and 500mg ceftriaxone, respectively. The most common adverse events reported by patients taking zoliflodacin included self-limited gastrointestinal symptoms.

RELATED REPORTS

Testing for sexually transmitted infections is infrequent among high school students in the United States

Quick Take: Gentamicin compared with ceftriaxone for the treatment of gonorrhoea (G-ToG)

2 Minute Medicine Rewind May 6, 2019

Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc

Tags: gonorrhea
Previous Post

The TARGET: Energy density of enteral nutrition not associated with mortality

Next Post

Inhaled inorganic nitrites do not improve exercise capacity in heart failure with preserved ejection fraction

RelatedReports

AAP opposes school-based drug testing of adolescents
Chronic Disease

Testing for sexually transmitted infections is infrequent among high school students in the United States

April 11, 2022
Quick Take: Gentamicin compared with ceftriaxone for the treatment of gonorrhoea (G-ToG)
Infectious Disease

Quick Take: Gentamicin compared with ceftriaxone for the treatment of gonorrhoea (G-ToG)

May 14, 2019
Government-funded initiatives provide important supports to low-income HIV patients
Weekly Rewinds

2 Minute Medicine Rewind May 6, 2019

May 10, 2019
Pre-exposure prophylaxis (PrEP) effective in preventing HIV infection in high-risk gay men
Chronic Disease

Pre-exposure HIV prophylaxis may lead to riskier behavior and increased STIs

April 10, 2019
Next Post

Inhaled inorganic nitrites do not improve exercise capacity in heart failure with preserved ejection fraction

Reperfusion therapy may be suboptimal for STEMIs requiring transfers

Sensitive cardiac injury marker could reduce stress testing for myocardial ischemia

Pre-operative transcranial magnetic stimulation useful for language mapping

Symptom improvement after concussion in pediatric patients expected within four weeks

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • SAR-CoV-2 infection during pregnancy may lead to adverse neurodevelopmental outcomes in male offspring
  • Hyperfractionated radiotherapy reduces complication rates compared to standard fractionation for locally advanced nasopharyngeal carcinoma
  • Lebrikizumab effective in treating moderate-to-severe atopic dermatitis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options